53 results about "Non clinical" patented technology

Methods of monitoring and evaluating the status of a tumor undergoing treatment includes monitoring in vivo at least one physiological parameter associated with a tumor in a subject undergoing treatment, transmitting data from an in situ located sensor to a receiver external of the subject, analyzing the transmitted data, repeating the monitoring and transmitting steps at sequential points in time and evaluating a treatment strategy. The method provides dynamic tracking of the monitored parameters over time. The method can also include identifying in a substantially real time manner when conditions are favorable for treatment and when conditions are unfavorable for treatment and can verify or quantify how much of a known drug dose or radiation dose was actually received at the tumor. The method can include remote transmission from a non-clinical site to allow oversight of the tumor's condition even during non-active treatment periods (in between active treatments). The disclosure also includes monitoring systems with in situ in vivo biocompatible sensors and telemetry based operations and related computer program products.

An electroencephalogram (EEG) utilizing epileptiform activity detection, warning and recording system adapted for use by non-healthcare professionals or healthcare professionals. The system is simple enough for use by untrained personnel and will be self-contained, not requiring technical setup or point of use maintenance. The system includes a small number of passive or active scalp electrodes for capturing the electrical signals in the subject's brain allowing for detection of epileptiform activity. The system will recognize epileptiform activity and will either transmit signals upon detection of epileptiform activity to either a localized warning device or to a cellular or radio receiving device. The system will note epileptiform activity in a recording component and allow for review of the epileptiform data to allow non-clinical and clinical personnel to verify such activity.

Behavioral clustering of providers may be used to identify outliers of a group of providers. Groups of healthcare providers may be built based on analysis of clinical information related to medical treatments. A plurality of subgroups of healthcare providers may be constructed in the groups, based on analysis of non-clinical information related to demographical information. First-level outlier healthcare providers may be removed from a particular group of healthcare providers, and second-level outlier healthcare providers may be removed from a particular subgroup of healthcare providers. The second-level outlier healthcare providers removed from the particular subgroup may remain in a group that contains the particular subgroup.

This disclosure describes, among other things, a method for recommending treatments for a condition (e.g., a medical condition). The method may include generating ranking treatments for a condition based on patient information. The patient information may identify one or more characteristics of a patient. The patient information may include clinical and/or non-clinical information. The treatments may be ranked based on a prediction of the degree to which the patient will be satisfied with the treatment. The prediction may be based on the degree to which other patients were satisfied with the treatment.

A method of making a diagnosis of a dental condition of a patient includes the steps of collecting non-imaging data relating to the patient, storing the non-imaging data in a storage medium containing stored non-imaging data and existing imaging data for this patient and for a plurality of other patients and applying non-real time and non-user attended algorithms to the stored non-imaging data and the existing imaging data of this patient and other patients. The algorithms determine the diagnosis of the dental condition of the patient. The diagnosis either is complete or determines what new dental imaging data for the patient is required to be acquired to diagnose the dental condition of the patient. The non-imaging data includes non-clinical data and non-dental clinical data.

A hearing device test system for use by a non-expert user may include a hearing device comprising a sound processor and a speaker and a portable test unit including a test microphone acoustically coupled to an exterior of the portable test unit via an acoustic calibration cavity. The portable test unit may include a coupler at an opening to the acoustic calibration cavity configured to receive the hearing device at least partially therein and the test microphone may be configured to produce a calibration signal input responsive to acoustic calibration stimuli provided by the speaker of the hearing device. The hearing device test system may also include a processor associated therewith and configured to measure a level of the calibration signal input.

A method of doing business is disclosed for the sale of insurance options. An individual is assigned a Health Risk Score (HRS); in a preferred embodiment, the HRS is determined by using an automated case-based method for assessing risk. The individual may then purchase an option for insurance coverage that will begin only after a predetermined period of time. At the beginning of that period, the individual's HRS is re-evaluated, and if it remains within predetermined acceptable limits, the individual may then obtain insurance coverage with premiums and benefits defined at the time of the purchase of the option. A case-based method for assessing risk is disclosed, in which various risk factors and their combinations are used to provide a scoring matrix. This scoring matrix is then used to evaluate the individual's HRS.

A system provides clinicians with realtime medication suggestions. A treatment decision support system comprises at least one repository including information associating candidate treatment items, treatment costs, treatment supply availability, patient specific medical information and corresponding related treatment parameters. An individual treatment item is associated with multiple related treatment parameters. A communication processor accesses the information in the at least one repository. A treatment decision processor uses accessed information provided by the communication processor for providing data representing candidate treatments in response to user entry of data identifying an initial treatment based on both clinical and non-clinical factors. The non-clinical factors include lowest cost and availability and the clinical factors include patient specific medical information and predetermined treatment guidelines for treating a particular medical condition. A display processor provides data representing at least one display image identifying the candidate treatments.

The present invention is a method of making a diagnosis of a dental condition of a patient which includes the steps of collecting non-imaging data relating to the patient, storing the non-imaging data in a storage medium containing stored non-imaging data and existing imaging data for this patient and for a plurality of other patients and applying non-real time and non-user attended algorithms to the stored non-imaging data and the existing imaging data of this patient and other patients. The algorithms determine the diagnosis of the dental condition of the patient. The diagnosis either is complete or determines what new dental imaging data for the patient is required to be acquired to diagnose the dental condition of the patient. The non-imaging data includes non-clinical data and non-dental clinical data.

The invention relates to a method for establishing a CYP2D1 gene knockout rat model, and belongs to the technical field of transgenosis. The method comprises the steps of firstly determining a target point of a to-be-knocked gene and designing and synthesizing a primer sequence of the gene; inserting the primer sequence into a Cas9-gRNA-Bsal carrier subjected to enzyme digestion and performing amplification to obtain a target point sgRNA with a T7 promoter sequence; after in vitro transcription and purification, performing activity detection; micro-injecting active sgRNA and Cas9 RNA into a rat single-cell embryo to obtain a Founder rat; and after screening out a CYP2D1 gene knockout rat heterozygote, performing mating to obtain a homozygote individual, namely, a CYP2D1 gene knockout rat. The invention provides a preparation method replacing a mouse model with a P450 gene knockout rat model, so that a gene knockout technology is really fused in non-clinical safety evaluation of drugs and early toxicity of candidate drugs can be discovered.

The invention relates to a method for establishing a CYP2C11 gene knockout rat model, and belongs to the technical field of transgenosis. The method comprises the steps of firstly determining a target point of a to-be-knocked gene and designing and synthesizing a primer sequence of the gene; inserting the primer sequence into a Cas9-gRNA-Bsal carrier subjected to enzyme digestion and performing amplification to obtain a target point sgRNA with a T7 promoter sequence; after in vitro transcription and purification, performing activity detection; micro-injecting active sgRNA and Cas9 RNA into a rat single-cell embryo to obtain a Founder rat; and after screening out a CYP2C11 gene knockout rat heterozygote, performing mating to obtain a homozygote individual, namely, a CYP2C11 gene knockout rat. The invention provides a brand-new preparation method replacing a mouse model with a P450 gene knockout rat model, so that a gene knockout technology is really fused in non-clinical safety evaluation of drugs and early toxicity of candidate drugs can be discovered.

The invention belongs to the laboratory medicine technology field, which relates to a device and a method of utilizing saliva to execute clinical or non-clinical detecting HIV/AIDS virus. The device of utilizing saliva to execute clinical or non-clinical detecting HIV/AIDS virus includes a strip shape test kit, a columned liquid collecting filter, a piston, a sampling cup, a measuring pipette, phosphate buffer reagent and antihuman IgG antibody-gold colloid conjugate reagent. The invention also provides a method of using the device to execute clinical or non-clinical detecting for saliva. Through detecting the saliva sample, the invention can achieve the requirements of accurate, quick, convenient and secure clinical or non-clinical detecting of HIV/AIDS virus.

Certain embodiments of the present invention provide methods and systems for dynamic, two-stage archiving and/or retrieval of clinical data. Certain embodiments provide a method for dynamic, two-stage clinical data archiving. The method includes copying clinical data from a primary datastore to a staging datastore, wherein non-clinical data is retained at the primary datastore and not passed to the staging datastore. The method further includes copying the clinical data from the staging datastore to an archive datastore. The method also includes deleting the clinical data from the staging datastore after the clinical data has been copied to the archive datastore. In certain embodiments, data may be restored from the archive datastore to the primary datastore via the staging datastore similar to the archiving process described above.

What is disclosed is an apparatus for enabling privacy for patients undergoing breast cancer screening in a non-clinical setting. One embodiment of the present apparatus comprises an enclosure in which a person can remove one or more garments to expose their breasts to a thermal camera for breast cancer screening. The enclosure is such that at least the breast area of that person is shielded from view by third parties. The apparatus also comprises a thermal camera for capturing thermal images of the exposed breast area. The thermal camera is connected to a robotic arm that changes the camera angle relative to real-world coordinates so that thermal images can be taken of the breast area from any angle between a frontal view and a left/right lateral view. A processor which executes a software interface tool for semi-automated or automated breast cancer screening based on the thermal images of the breast.

The invention provides a non-intervention monitoring and evaluating method for hypertension under a non-clinical environment. The method comprises steps of segmenting acquired electrocardiogram data to obtain an electrocardiosignal sequence taking a time window of 5 minutes as a unit, positioning the time of each heartbeat by using an overlapping sliding window algorithm, and calculating a primaryheartbeat interval sequence; correcting the acquired primary heartbeat interval sequence by adopting a threshold method; extracting linear domain, non-linear domain and waveform distribution morphological features from the heartbeat interval sequence of each time window, quantitatively calculating correlation between the heart rate variability linear domain and the non-linear domain features through a Pearson correlation analysis method, performing feature aggregation based on the correlation strength between the features, and selecting features through information gain to form feature subsets; and fusing the feature subset features, and constructing a hypertension evaluation model by using a random forest method. According to the method, finer granularity analysis is carried out, and evaluation accuracy rate of hypertension patients can reach 97.1%.

The invention relates to a composite disease clinical path construction method and system based on transfer learning. The method comprises the following steps: acquiring multi-source heterogeneous medical data of a composite disease generated by a non-clinical path; structuring the data according to ICD classification to form a first data set; performing feature extraction and clustering on the first data set according to the sign information, the medical staging, the diagnosis information and the treatment evaluation to form a second data set; randomly extracting data sets of two disease types from the second data set, training a time domain convolutional neural network to learn one disease type data set, and adjusting the time domain convolutional neural network through MMD to be used for transfer learning of the other disease type data set; and finally, fusing according to an output result to obtain a composite disease clinical path. By simplifying the data set and integrating the data set with the time domain convolutional neural network and the generative adversarial neural network, the performance and interpretability of a composite disease clinical path structure are improved, and gradient explosion is avoided.

The invention discloses a UHPLC-MS/MS (Ultra High Performance Liquid Chromatography-Mass Spectrometry-Mass Spectrometry) analytical method for measuring rat curcumin plasma concentration. The method comprises the following steps: (1) preparing a curcumin standard solution and an internal standard tinidazole standard solution, and establishing a standard curve; and (2) adding an internal standard into to-be-measured plasma, performing pretreatment, performing LC-MS/MS analysis, and calculating the concentration of curcumin in the to-be-measured plasms by utilizing the standard curve. According to the method disclosed by the invention, the chromatographic conditions and internal standard substances are reasonably selected, the sensitivity is improved, the analysis time is shortened, and the sample pretreatment process is simplified. Meanwhile, the method disclosed by the invention has high accuracy and precision degree, and the detection requirements of non-clinical pharmacokinetic study are met.

A oligonucleotide probe containing specific probe and switch sequences for in vitro, in vivo and intracellular detection and identification of target sequences and molecules. Methods of using such probes for the detection of target sequences and molecules in various cells and tissues as well as a variety of biological samples and fluids. Methods of using such probes in non-clinical areas, such as agriculture.

The invention relates to three non-clinical antitumor drugs which are found to have anti-tumor effects and mainly can inhibit the proliferation of lung cancer A549 cells or cervical cancer Hela cells. The technical problem to be solved is that some clinical drugs are screened by using the lung cancer A549 cells and the cervical cancer Hela cells, so as to obtain the non-clinical antitumor drugs with the antitumor effects. Key points of technical schemes for solving the problems are as follows: the lung cancer A549 cells and the cervical cancer Hela cells are processed for 48 hours by using drugs of saturated concentration, and the changes of the morphology and quantity of the cells are observed by a microscope; for drugs with inhibitory actions, survival rate and LDH (Lactate Dehydrogenase) activity detection is further carried out on the cells, and Hoechst33258 is applied to cell apoptosis detection. Main purposes: the non-clinical anticancer drugs for remarkably inhibiting the proliferation of the lung cancer A549 cells or cervical cancer Hela cells are found and are applied to the clinical treatment of patients with lung cancer or cervical cancer.